Animal experiments indicate that acidic fibroblast growth factor (aFGF) and basic fibroblast growth factor (bFGF) are involved in regulating cardiac angiogenesis and repair, suggesting their potential as therapeutic agents for the treatment of DCM (50). The gene discussed is FGF2; the disease is familial dilated cardiomyopathy.